{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:09:40Z","timestamp":1794373780463,"version":"4.9.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8086","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,10,23]]},"DOI":"10.1038\/s41586-025-09489-8","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T15:02:49Z","timestamp":1758726169000},"page":"953-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma"],"prefix":"10.1038","volume":"646","author":[{"given":"Nelson H.","family":"Knudsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9177-0251","authenticated-orcid":false,"given":"Giulia","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Korell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamina","family":"Kienka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Nobrega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4778-8742","authenticated-orcid":false,"given":"Maria","family":"Zschummel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6957-9903","authenticated-orcid":false,"given":"Alexander","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Bouffard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Kann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie","family":"Goncalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans W.","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Pezeshki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette S. M. T.","family":"Suermondt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merle","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trisha R.","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2701-3114","authenticated-orcid":false,"given":"Sangwoo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Salas-Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah P.","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Birocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-0221","authenticated-orcid":false,"given":"Mark B.","family":"Leick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca C.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-9889","authenticated-orcid":false,"given":"John G.","family":"Doench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-8284","authenticated-orcid":false,"given":"Debattama","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-5573","authenticated-orcid":false,"given":"Kathleen B.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1336-413X","authenticated-orcid":false,"given":"Robert T.","family":"Manguso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"9489_CR1","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H., O\u2019Connor, R. S., Kawalekar, O. U., Ghassemi, S. & Milone, M. C. CAR-T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"9489_CR2","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"9489_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"9489_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug Discov. 22, 976\u2013995 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9489_CR5","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"9489_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"9489_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj4008","volume":"375","author":"R Schmidt","year":"2022","unstructured":"Schmidt, R. et al. CRISPR activation and interference screens decode stimulation responses in primary human T cells. Science 375, eabj4008 (2022).","journal-title":"Science"},{"key":"9489_CR8","doi-asserted-by":"publisher","first-page":"eade3369","DOI":"10.1126\/sciimmunol.ade3369","volume":"8","author":"JE Wu","year":"2023","unstructured":"Wu, J. E. et al. In vitro modeling of CD8+ T cell exhaustion enables CRISPR screening to reveal a role for BHLHE40. Sci. Immunol. 8, eade3369 (2023).","journal-title":"Sci. Immunol."},{"key":"9489_CR9","doi-asserted-by":"publisher","first-page":"E4051","DOI":"10.1073\/pnas.1801340115","volume":"115","author":"W Shang","year":"2018","unstructured":"Shang, W. et al. Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation. Proc. Natl Acad. Sci. USA 115, E4051\u2013E4060 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9489_CR10","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1146\/annurev-immunol-042718-041522","volume":"37","author":"DR Simeonov","year":"2019","unstructured":"Simeonov, D. R. & Marson, A. CRISPR-based tools in immunity. Annu. Rev. Immunol. 37, 571\u2013597 (2019).","journal-title":"Annu. Rev. Immunol."},{"key":"9489_CR11","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1158\/2159-8290.CD-20-1243","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang, D. et al. CRISPR screening of CAR-T cells and cancer stem cells reveals critical dependencies for cell-based therapies. Cancer Discov. 11, 1192\u20131211 (2021).","journal-title":"Cancer Discov."},{"key":"9489_CR12","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.cell.2018.10.024","volume":"175","author":"E Shifrut","year":"2018","unstructured":"Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958\u20131971 (2018).","journal-title":"Cell"},{"key":"9489_CR13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-022-05126-w","volume":"609","author":"J Carnevale","year":"2022","unstructured":"Carnevale, J. et al. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174\u2013182 (2022).","journal-title":"Nature"},{"key":"9489_CR14","doi-asserted-by":"publisher","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas, K. A. et al. Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647 (2022).","journal-title":"Science"},{"key":"9489_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2021.02.019","volume":"184","author":"Z Chen","year":"2021","unstructured":"Chen, Z. et al. In vivo CD8+ T cell CRISPR screening reveals control by Fli1 in infection and cancer. Cell 184, 1262\u20131280 (2021).","journal-title":"Cell"},{"key":"9489_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019).","journal-title":"Nature"},{"key":"9489_CR17","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"9489_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman, K. M. et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum. Gene Ther. 29, 585\u2013601 (2018).","journal-title":"Hum. Gene Ther."},{"key":"9489_CR19","doi-asserted-by":"publisher","first-page":"6223","DOI":"10.3390\/ijms20246223","volume":"20","author":"S Stock","year":"2019","unstructured":"Stock, S., Schmitt, M. & Sellner, L. Optimizing manufacturing protocols of chimeric antigen receptor T cells for improved anticancer immunotherapy. Int. J. Mol. Sci. 20, 6223 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"9489_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol. 20, 31\u201342 (2019).","journal-title":"Lancet Oncol."},{"key":"9489_CR21","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750\u20133759 (2014).","journal-title":"Blood"},{"key":"9489_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","volume":"121","author":"N Cieri","year":"2013","unstructured":"Cieri, N. et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121, 573\u2013584 (2013).","journal-title":"Blood"},{"key":"9489_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3389\/fimmu.2019.00263","volume":"10","author":"CJ Dwyer","year":"2019","unstructured":"Dwyer, C. J. et al. Fueling cancer immunotherapy with common \u03b3 chain cytokines. Front. Immunol. 10, 263 (2019).","journal-title":"Front. Immunol."},{"key":"9489_CR24","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.BCD-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein, M. et al. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2, 408\u2013422 (2021).","journal-title":"Blood Cancer Discov."},{"key":"9489_CR25","doi-asserted-by":"publisher","first-page":"101212","DOI":"10.1016\/j.omtm.2024.101212","volume":"32","author":"C Amatya","year":"2024","unstructured":"Amatya, C. et al. Optimization of anti-CD19 CAR T cell production for treatment of patients with chronic lymphocytic leukemia. Mol. Ther. Methods Clin. Dev. 32, 101212 (2024).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"9489_CR26","doi-asserted-by":"publisher","first-page":"102082","DOI":"10.1016\/j.xpro.2023.102082","volume":"4","author":"SK Lane-Reticker","year":"2023","unstructured":"Lane-Reticker, S. K. et al. Protocol for in vivo CRISPR screening using selective CRISPR antigen removal lentiviral vectors. STAR Protoc. 4, 102082 (2023).","journal-title":"STAR Protoc."},{"key":"9489_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04013-1","volume":"9","author":"NPD Liau","year":"2018","unstructured":"Liau, N. P. D. et al. The molecular basis of JAK\/STAT inhibition by SOCS1. Nat. Commun. 9, 1558 (2018).","journal-title":"Nat. Commun."},{"key":"9489_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood.V97.1.221","volume":"97","author":"B Sporri","year":"2001","unstructured":"Sporri, B., Kovanen, P. E., Sasaki, A., Yoshimura, A. & Leonard, W. J. JAB\/SOCS1\/SSI-1 is an interleukin-2-induced inhibitor of IL-2 signaling. Blood 97, 221\u2013226 (2001).","journal-title":"Blood"},{"key":"9489_CR29","doi-asserted-by":"publisher","first-page":"107957","DOI":"10.1016\/j.celrep.2020.107957","volume":"32","author":"M Flosbach","year":"2020","unstructured":"Flosbach, M. et al. PTPN2 deficiency enhances programmed T cell expansion and survival capacity of activated T cells. Cell Rep. 32, 107957 (2020).","journal-title":"Cell Rep."},{"key":"9489_CR30","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/S0960-9822(02)00697-8","volume":"12","author":"PD Simoncic","year":"2002","unstructured":"Simoncic, P. D., Lee-Loy, A., Barber, D. L., Tremblay, M. L. & McGlade, C. J. The T cell protein tyrosine phosphatase is a negative regulator of Janus family kinases 1 and 3. Curr. Biol. 12, 446\u2013453 (2002).","journal-title":"Curr. Biol."},{"key":"9489_CR31","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/nature07924","volume":"458","author":"K Matsushita","year":"2009","unstructured":"Matsushita, K. et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature 458, 1185\u20131190 (2009).","journal-title":"Nature"},{"key":"9489_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.cell.2015.04.029","volume":"161","author":"T Mino","year":"2015","unstructured":"Mino, T. et al. Regnase-1 and roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. Cell 161, 1058\u20131073 (2015).","journal-title":"Cell"},{"key":"9489_CR33","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s41590-021-01064-3","volume":"22","author":"G Behrens","year":"2021","unstructured":"Behrens, G. et al. Disrupting roquin-1 interaction with regnase-1 induces autoimmunity and enhances antitumor responses. Nat. Immunol. 22, 1563\u20131576 (2021).","journal-title":"Nat. Immunol."},{"key":"9489_CR34","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2013.04.034","volume":"153","author":"T Uehata","year":"2013","unstructured":"Uehata, T. et al. Malt1-induced cleavage of regnase-1 in CD4+ helper T cells regulates immune activation. Cell 153, 1036\u20131049 (2013).","journal-title":"Cell"},{"key":"9489_CR35","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"9489_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43416-7","volume":"14","author":"RC Larson","year":"2023","unstructured":"Larson, R. C. et al. Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma. Nat. Commun. 14, 7509 (2023).","journal-title":"Nat. Commun."},{"key":"9489_CR37","doi-asserted-by":"publisher","first-page":"6298","DOI":"10.1158\/1078-0432.CCR-21-1559","volume":"27","author":"J Lemoine","year":"2021","unstructured":"Lemoine, J., Ruella, M. & Houot, R. Overcoming intrinsic resistance of cancer cells to CAR T-cell killing. Clin. Cancer Res. 27, 6298\u20136306 (2021).","journal-title":"Clin. Cancer Res."},{"key":"9489_CR38","doi-asserted-by":"publisher","first-page":"3451","DOI":"10.1158\/0008-5472.CAN-19-3663","volume":"80","author":"SF Razavipour","year":"2020","unstructured":"Razavipour, S. F., Harikumar, K. B. & Slingerland, J. M. p27 as a transcriptional regulator: new roles in development and cancer. Cancer Res. 80, 3451\u20133458 (2020).","journal-title":"Cancer Res."},{"key":"9489_CR39","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"9489_CR40","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1056\/NEJMoa2411507","volume":"392","author":"K Perica","year":"2025","unstructured":"Perica, K. et al. CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53. N. Engl. J. Med. 392, 577\u2013583 (2025).","journal-title":"N. Engl. J. Med."},{"key":"9489_CR41","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat. Med. 30, 984\u2013989 (2024).","journal-title":"Nat. Med."},{"key":"9489_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"9489_CR43","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1182\/blood.2020009309","volume":"138","author":"W Zheng","year":"2021","unstructured":"Zheng, W. et al. Regnase-1 suppresses TCF-1+ precursor exhausted T-cell formation to limit CAR-T-cell responses against ALL. Blood 138, 122\u2013135 (2021).","journal-title":"Blood"},{"key":"9489_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09656-2","volume":"10","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. A CRISPR\u2013Cas9 delivery system for in vivo screening of genes in the immune system. Nat. Commun. 10, 1668 (2019).","journal-title":"Nat. Commun."},{"key":"9489_CR45","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1038\/s41590-019-0480-4","volume":"20","author":"MW LaFleur","year":"2019","unstructured":"LaFleur, M. W. et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity. Nat. Immunol. 20, 1335\u20131347 (2019).","journal-title":"Nat. Immunol."},{"key":"9489_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2024.02.016","volume":"42","author":"C-P Lin","year":"2024","unstructured":"Lin, C.-P. et al. Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness. Cancer Cell 42, 623\u2013645 (2024).","journal-title":"Cancer Cell"},{"key":"9489_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30196-9","volume":"13","author":"R Li","year":"2022","unstructured":"Li, R. et al. Comparative optimization of combinatorial CRISPR screens. Nat. Commun. 13, 2469 (2022).","journal-title":"Nat. Commun."},{"key":"9489_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09489-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09489-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T07:02:43Z","timestamp":1761202963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09489-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":48,"journal-issue":{"issue":"8086","published-print":{"date-parts":[[2025,10,23]]}},"alternative-id":["9489"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09489-8","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.V.M., N.H.K., F.K., T.R.B. and R.T.M. are inventors on patents filed by MGH and the Broad Institute on these technologies. M.V.M. is an inventor on patents related to adoptive cell therapies, held by MGH (some licensed to ProMab and Luminary) and the University of Pennsylvania (some licensed to Novartis). M.V.M. holds equity in 2seventy bio, A2 Bio, AffyImmune, BendBio, Cargo, GBM newco, Model T bio, NexImmune and Oncternal. M.V.M. receives grant and\/or research support from Kite Pharma, Moderna and Sobi. M.V.M. has served as a consultant for multiple companies involved in cell therapies. M.V.M.\u2019s competing interests are managed by Mass General Brigham. R.T.M. has received consulting or speaking fees from Bristol Myers Squibb, Gilead Sciences and Immunai Therapeutics, has equity ownership in OncoRev and receives research funding from Calico Life Sciences. M.B.L. is an inventor on patents related to adoptive cell therapies held by MGH and has served as a consultant for BioNTech and Cabaletta Bio. M.B.L. holds equity in AbbVie. R.C.L. is an inventor on patents related to adoptive cell therapies held by MGH, has served as a consultant for Cargo and is now an employee of Link Cell Therapies. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}